RegenCell BioScience Holdings (RGC)

[shinhari1309]

RGC, share float and ceo buyback.
About Regencell Bioscience (RGC)
Regencell Bioscience is an early clinical stage bioscience company using traditional Chinese medicine (TCM) approach to develop standardized TCM formulas to holistically treat autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) in children, and infectious diseases which affects the immune system such as COVID-19.

Share float
Companies may decide to increase their float by issuing new shares as a way to raise capital or encourage more trading. But they may also choose to reduce their float through a stock buyback, which can result in increasing the value of shares. This usually happens if the company believes its shares have been discounted too much, wants to invest in itself, or wants to see its financial ratios go up.

CEO share buyback
CEO of RGC recently bought US$886k worth of stock. On the 25th of July, Yat-Gai Au bought around 22k shares on-market at roughly US$39.48 per share. In the last 3 months, they made an even bigger purchase worth US$1.2m. Yat-Gai has been a buyer over the last 12 months, purchasing a net total of US$2.7m worth in shares.

Until the company's market valuation reaches $1 billion, the CEO of RGC vows to assist Regencell by taking a $1 annual salary with no bonuses. Additionally, he has set aside share options for everyone but himself. He had taken the initiative in utilising more than $5.9 million of my personal assets to buy shares on the open market.

Additionally, the management group and directors have agreed to collectively extend the lock-up obligations on their stock options.

https://www.benzinga.com/news/small-cap/22/06/27852402/rgc-ceo-figuratively-putting-his-money-where-his-mouth-is